Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

APOC3 antibody (FITC)

The Goat Polyclonal anti-APOC3 antibody has been validated for . It is suitable to detect APOC3 in samples from Human.
Catalog No. ABIN7454059

Quick Overview for APOC3 antibody (FITC) (ABIN7454059)

Target

See all APOC3 Antibodies
APOC3 (Apolipoprotein C-III (APOC3))

Reactivity

  • 47
  • 36
  • 30
Human

Host

  • 61
  • 9
  • 6
Goat

Clonality

  • 67
  • 9
Polyclonal

Conjugate

  • 33
  • 10
  • 7
  • 5
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
This APOC3 antibody is conjugated to FITC

Application

Please inquire

Clone

F09
  • Purpose

    Goat anti-Human Apo CIII [F09] Antibody FITC Conjugated

    Immunogen

    Human Apolipoprotein CIII

    Isotype

    IgG
  • Restrictions

    For Research Use only
  • Concentration

    1 mg/mL

    Buffer

    75 mM Sodium Phosphate, 75 mM NaCl, 0.5 mM EDTA, 0.02 % Sodium azide, pH 7.2

    Preservative

    Sodium azide

    Precaution of Use

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Storage

    4 °C

    Expiry Date

    12 months
  • Target

    APOC3 (Apolipoprotein C-III (APOC3))

    Alternative Name

    ApoCIII

    Background

    Background: Apo CIII contains 79 amino acid residues. The m.w. is 8.7 kDa (Brewer et al., 1974). It may inhibit the activation of lipoprotein lipase by apo CIII. Apo CIII is a constituent of both apoB- and apoAI-containing lipoproteins in the circulation. Apo CIII plays a pivotal role in regulating the plasma metabolism of VLDL, IDL, and LDL, primarily by inhibiting receptor-mediated uptake of these lipoproteins by the liver. (Sehayek and Eisenberg 1991, Aalto-Setala et al., 1992, Zheng et al., 2007)

    Gene ID

    345

    NCBI Accession

    NP_000031

    UniProt

    P02656

    Pathways

    Carbohydrate Homeostasis, Lipid Metabolism
You are here:
Chat with us!